NK cell therapy for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests adding donor natural killer (NK) cells to standard chemoradiation for advanced nasopharyngeal cancer. It aims to see if this combination helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage III or IVA/B nasopharyngeal cancer that has not spread to other parts of the body.
- You need to be able to handle standard chemotherapy and radiation treatment.
- Your Epstein-Barr virus (EBV) levels in the blood should be detectable at diagnosis.
- You must have adequate kidney and liver function, as well as enough white blood cells and platelets.
- You should be in good daily health (able to do most activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.